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Propafenone, a new antiarrhythmic agent, was utilized
in 30 patients with diverse heart disease who presented
with sustained hemodynamically unstable ventricular
arrhythmia. Drug efficacy was judged by means of am-
bulatory electrocardiographic monitoring and exercise
testing. Nine patients additionally had invasive electro-
physiologic studies.
Seventeen patients (57%) responded to therapy as
judged by monitoring and 21 patients (70%) responded
to therapy as judged by exercise testing. When both
methods were considered, 16 patients (53%) responded.
The acute drug test predicted the result of maintenance
therapy in 91% of patients. Seven of nine patients who
had electrophysiologic testing responded based on this
technique, and in all cases the results were concordant
with the noninvasive evaluation. Serum blood levels did
Six drugs including quinidine, procainamide and disopyr-
amide, which are effective when given orally, are now widely
used in the United States for suppressing ventricular ar-
rhythmias. However, these drugs are often ineffective and
may cause serious and even life-threatening adverse reac-
tions. As the number of patients with ventricular arrhythmias
continuously increases, there is a pressing need for new
drugs. Propafenone is one such new agent that has proved
effective in suppressing ventricular and supraventricular ar-
rhythmias, including those associated with the Wolff-Par-
kinson-White syndrome (1-3). However, little is known
concerning its efficacy for preventing ventricular tachy-
cardia or fibrillation. In this study, we report our experience
with propafenone in patients who have had recurrent and
sustained ventricular arrhythmias that were hemodynami-
cally unstable.
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not correlate with antiarrhythmic effect. In patients with
myocardial impairment, echocardiographic assessment
of left ventricular function indicated a decrease in ejec-
tion fraction during propafenone therapy (32 versus 24%,
p < 0.05), while no change was observed in patients with
normal left ventricular function.
Side effects occurred in nine patients and included
exacerbation of congestive heart failure, development of
conduction abnormalities and aggravation of arrhyth-
mia, each occurring in two patients. Ten patients who
continued on long-term propafenone therapy for an av-
erage of 10 months (range 3 to 13) have remained free
of arrhythmia and side effects. Propafenone needs to be
employed with caution in patients with congestive heart
failure or evidence of conduction system disease.
Methods
Study patients (Table 1). The study group consisted of
30 patients, ranging in age from 15 to 74 years (mean 56);
22 were male and 8 were female. These patients were re-
ferred because of sustained and hemodynamically significant
ventricular tachyarrhythmia refractory to conventional drugs.
The group included 21 patients who had ventricular tachy-
cardia with hemodynamic instability manifested clinically
by hypotension, dizziness and syncope and 9 patients who
had experienced ventricular fibrillation. In all cases, car-
dioversion or defibrillation was necessary to convert the
arrhythmia, The cardiac diagnosis included coronary artery
disease in 19 patients, cardiomyopathy in 5 patients, val-
vular heart disease in 2 patients and no structural heart
disease in 4 patients. Fourteen patients had chronic conges-
tive heart failure requiring digoxin and diuretic drugs to
achieve cardiac compensation. All patients had previously
received quinidine, procainarnide, disopyramide and pro-
pranolol; these drugs either proved ineffective or caused
intolerable side effects. Eight patients had 2 episodes of
sustained arrhythmia, 22 patients had 3 episodes and 9 pa-
tients had more than 10 episodes.
Control study protocol: phase O. On admission to a
special ward for telemetered electrocardiographic monitor-
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ing , drugs were discontinued with the exception of those
required for managing heart failure or angina pectoris . In
the latter case, it included nitrates , calcium blocking drugs
and beta-adrenergic blocking agents. A drug-free washout
period of 36 to 48 hours preceded the study. At the end of
this washout, patients entered phase 0 studies. This phase
consisted of 48 hours of ambulatory monitoring with a cas-
sette tape recorder (4) and a maximal exercise test on a
motorized treadmill adhering to a Bruce protocol (5).
Arrhythmias were coded according to the Lawn grading
system (6, 7):
Salvos of ventricular tachycardia were provoked in 20 pa-
tients with an average of 13 runs per test (range I to 47).
Acute drug testing: phase 1. At the conclusion of con-
trol studies, the patient entered phase I investigations in-
volving acute drug testing , the details of which have been
previously reported (6). The essential s of such testing con-
sist of the following elements: a baseline monitoring period
of 30 minutes , during which an on-line arrhythmia record
was obtained by trendscription (8), as well as exercise test-
ing on a bicycle ergometer. These constituted the control
data for subsequent comparison of drug efficacy. Thereafter,
an oral dose of propafenone, 450 mg, was administered.
Monitoring by trendscription was continued for 3 hours,
while bicycle ergometry was repeated hourly. Before each
bicycle exercise test, blood pressure , heart rate and electro-
cardiographic intervals recorded at 50 mm/s were obtained .
Maintenance period: phase 2. Once acute drug testing
was completed, the patient entered phase 2 for a short main-
tenance interval during which dosing with propafenone was
extended for 72 to 96 hours. The dose schedule employed
was 150 mg three times daily on days I and 2, and 300 mg
three times daily on days 3 and 4; this was the maximal
dose permitted. Increase in dosage was guided by the effect
of the drug on arrhythmia as determined by telemetered
monitoring and the occurrence of side effects . On day 4,
ambulatory monitoring for 24 hours was repeated , a symp-
tom-limited exercise test on a motorized treadmill was per-
formed and blood samples for propafenone level determi-
nations were obtained 2 hours after a dose.
Criteria for drug efficacy during the phase I acute drug
test and phase 2 monitoring and exercise testing included
thefollowing: I) Total elimination of all salvos of ventricular
tachycardia (grade 4B). 2) A greater than 90% reduction in
the frequency of couplets (grade 4A). 3) On monitoring, a
greater than 50% decrease in the number of ventricular
premature beats per hour and a greater than 50% decrease
in the number of hours of grade 2 ventricular premature
beats. During exercise testing, a greater than 50% reduction
in the number of ventricular premature beats per test.
Electrophysiologic study. In nine patients, electro-
physiologic studies were also performed. In three patients ,
these invasive studies were mandated for assessing drug
action because of a paucity of ventricular arrhythmia. The
electrophysiologic methods have been described (9) and
included the following key elements: A 6 French hexapolar
electrode catheter was inserted into the left subclavian vein
under fluoroscopic guidance and positioned in the right ven-
tricular apex. Up to three extrastimuli (S I, S2, S3) were
administered during both sinus rhythm and ventricular pac-
ing (500 ms cycle length) at energies of twice and three
times mid-diastolic threshold. The end point was nonsus-
tained ventricular tachycardia defined as three or more suc-
cessive repetitive ventricular responses elicited by the last
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Patients (no.)
Male
Female
Mean age (yr)
Range
Cardiac diagnosis
Coronary artery disease
Cardiomyopathy
Valvular disease
No structural disease
grade 3
grade 4A
grade 4B
Ventricular tachycardia
Ventricular fibrillation
Congestive heart failure
Table 1. Study Patients
grade 0 = no ventricular premature beats
grade lA = occasional, isolated ventricular premature beats
« 30 per hour); less than IImin
grade IB = occasional, isolated ventricular premature beats
« 30 per hour); more than IImin
grade 2 = frequent ventricular premature beats (> 30 per
hour)
:;= multiform ventricular premature beats
= repetitive ventricular premature beats, couplets
= repetitive ventricular premature beats , salvos
(ventricular tachycardia)
grade 5 = early ventricular premature beats (abutting or
interrupting the T wave).
In these 30 patients, the average hourly ventricular pre-
mature beat frequency was 554 (range 20 to 2,303) . Sev-
enteen patients had 100 to 500 ventricularpremature beats/hour
and 13 had more than 500. Couplets were present for more
than 50% of the hours monitored in 23 patients and averaged
71/hour. Salvos of ventricular tachycardia were recorded in
26 patients with an average of 17 runs/hour (range I to 246) .
Sixteen patients had ventricular tachycardia for more than
50% of the hours monitored.
The average number of ventricular premature beats per
exercise test was 202 (range 26 to 665) . Couplets occurred
in 25 patients at a frequency of 35 per test (range 3 to 288).
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Figure 1. Results of phase 2 monitoring. For the
entire group of 30 patients and the 17 responders
(Resp) , propafenone significantly reduced the num-
ber of ventricular premature beats (VPBs), couplets
and salvos of ventricular tachycardia (VT) per hour.
In those who did not respond (NResp) , only the
reduction in couplets was significant.
Resp NResp
(p<o.oll (p. N.5.)
o Control
Propofenone
Resp NResp
(po O.Oll (poO.05)
Resp NResp
(poO.05) ( poO.1)
stimulated premature beat. On completion of the control
electrophysiologic study, propafenone administration was
begun on a schedule as previously outlined and continued
for n to 96 hours after which electrophysiologic testing
was repeated . Drug efficacy was assessed by the inability
to provoke multiple repetitive ventricular responses (more
than two).
Et..hocardiography. M-mode echocardiography was
performed during the control phase before drug administra-
tion and was repeated after 72 hours of propafenone therapy.
Measurements included end-systolic and end-diastolic di-
ameters, left ventricular posterior wall and septal excursions
as well as ejection time. Standard formulas were utilized to
calculate end-systolic and end-diastolic volumes, ejection
fraction and stroke volume index (10). Although such mea-
surernents may not be accurate in patients with segmental
wall abnormalities, the echocardiograms were used to detect
changes caused by the drug.
Long-term monitoring and study. If propafenone was
the most effective and best tolerated among the several
antiarrhythmic agents tested and did not induce side effects,
long-term management was initiated. Patients were seen
within I month and thereafte r at 3 month intervals . At each
visit, 24 hour monitorin g, exercise stress testing and echo-
cardiography were repeated. Drug dosage was adjusted de-
pending on the emergence of symptoms.
Determination of serum drug levels. Blood was ana-
lyzed for propafenone level by the method of Harapat and
Kates (11 ). One milliliter of plasma was added to 2N sodium
hydroxide and I% isoamyl alcohol in heptane . After mixing
VPBs Couplets VT
Figure 2. Results of phase 2 exercise testing. In 300 60 30
the 30 patients and the 21 responders (Resp), pro- 250 50 25
pafenone significantly reduced the number of ven-
tricu lar premature beats (VPBs), couplets and sal- NUMBER 200 40 20
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nine nonresponders (NResp), there was a significant TEST 150 30 15
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beats and couplets, but not in salvos of ventricular
tachycardia . Propafenone did not change exercise 50 10 5
duration , but there was a significant decrease in
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and centrifuging the organic layer was separated and added
to 0.2N phosphoric acid for analysis by high performance
liquid chromatography.
Statistical analysis. Statistical analysis was performed
by Student's t test for paired values and by the chi-square
method. Criterion of significance was a probability (p) value
of 0.05 or less. Results are expressed as mean ± standard
error of the mean (SEM).
Results
Acute drug testing. Of the 30 patients, 8 were not sub-
jected to this type of study because the arrhythmia was
primarily provoked either during treadmill exercise or with
electrophysiologic testing. The other 22 patients underwent
acute drug testing and received a single dose of 450 mg of
propafenone. Eleven patients had suppression of arrhythmia
meeting the defined criteria for drug efficacy. Onset of drug
effect was at 92 minutes (range 60 to 150). No untoward
effects were encountered and no significant changes in
electrocardiographic intervals were observed.
Phase 2 monitoring (Fig. 1). Each of the 30 patients
was involved in phase 2 of the study, 28 receiving 900 mg
of propafenone daily and 2 receiving 450 mg daily. The
hourly frequency of ventricular premature beats was reduced
from 554 to 174 (p = 0.00. The hourly frequency of
couplets decreased from 71 to 9 (p < 0.005) and the number
of hours that couplets were present was reduced from 16 to
10. The hourly frequency of salvos of ventricular tachy-
cardia was diminished from 17 to 0.3; however, because of
the great variability, this change was not significant. The
number of hours during which ventricular tachycardia oc-
curred decreased from 11 to 3. On the basis of monitoring
critera, 17 (57%) of the 30 patients responded. In the group
Table 2. Propafenone Blood Levels, Antiarrhythmic Response, Ejection Fraction and
Occurrence of Side Effects
Propafenone Ejection Fraction (%)
Blood Level
Case (ng/rnl) Control Drug Side Effects
Responders
I 766 61 61 No
2 469 33 33 Yes
3 821 58 63 No
4 864 50 63 No
5 1.627 44 28 No
6 1.l93 54 50 No
7 314 35 34 No
8 643 65 62 No
9 903 68 66 No
10 396 32 25 No
II 653 56 31 Yes
12 1,478 12 10 Yes
13 747 14 II Yes
14 411 27 25 No
15 423 60 57 No
16 1,018 41 41 No
Mean 794
Nonresponders
17 657 70 65 No
18 588 38 38 No
19 1,120 57 62 Yes
20 292 62 67 No
21 234 Yes
22 469 43 38 No
23 1,285 46 38 Yes
24 560 45 33 No
25 215 13 20 No
26 740 Yes
27 922 Yes
28 1,202 No
29 1,726 No
30 1,143 No
Mean 744
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of responders, the hourly number of ventricular premature
beats was reduced from 678 to 49 (p < 0.01). Couplets
were reduced from 88 to 0.2 per hour (p = 0.01), with a
decrease in the number of hours during which couplets oc-
curred from 16 to 4. Salvos of ventricular tachycardia by
definition were completely abolished.
In the 13 patients who did not respond to propafenone,
ventricular premature beat frequency remained unaltered
(35.1 versus 321). There was a significant decrease in the
hourly frequency of couplets (p = 0.05), but a nonsignifi-
cam reduction in the hourly prevalence of salvos of ven-
tricular tachycardia.
Phase 2 exercise testing (Fig. 2). Patients' exercise tol-
erance was not altered by propafenone (mean duration 6.2
versus 5.9 minutes). There was, however, a reduction in
peak heart rate with exercise from 142 during control testing
to 119 beats/min after propafenone (p < 0.05). For all
patients, there was a significant decrease in ventricular pre-
mature beats, couplets and ventricular tachycardia. Twenty-
om patients (70%) were considered to have responded to
propafenone as judged exclusively by exercise testing. In
the ,e patients, ventricular premature beats per test decreased
from 236 to 18, couplets from 50 to 3 and salvos of ven-
tricular tachycardia were eliminated.
Serum drug level and effect on arrhythmia (Table
2). When the results of both exercise testing and monitoring
were combined, 16 (53%) of the patients met the criteria
and were responders to propafenone (Fig. 3). The average
serum drug level in responders was 795 ng/ml (range 3 14
to 1,627). In the nonresponders, the average level was 744
Figure 3. Tracings from a propafenone responder. During phase
ocontrol studies, salvos of ventricular tachycardia (VT) are present
at rest, but become more frequent and of longer duration during
and after exercise (post exercise). After 4 days of propafenone
therapy, ventricular ectopic activity (VEA) is abolished. Although
exercise duration is essentially the same, peak heart rate (peak hr
in beats/min) achieved while taking propafenone is reduced.
ng/ml (range 215 to 1,726). There was no significant dif-
ference in these values. Eight patients had prolongation of
the PR interval during propafenone therapy from 0.18 to
0.23 second. However, there was no correlation between
the change in the PR interval, serum blood level (average
612 ng/rnl) and the effect of the drug on arrhythmia. There
were no significant changes in QRS or QT intervals.
Correlation between phases of drug testing (Table
3). Twenty-two patients were studied during both phase I
and 2. Of the II patients who had an effective response to
propafenone during phase I, 9 showed a similar response
during phase 2. None of the II who failed to respond during
Table 3. Correlation Between Phase I and Phase 2 Studies
Phase 2
Phase I Responders Nonresponders Total
Responders 9 2 II
Nonresponders 0 II II
Total 9 13 22
p < 0.01; X2 = 10.13; concordance 91%,
122 PODRID AND LOWN
PROPAFENONE
JACC Vol. 4. No. I
July \984:\ \7-25
value of less than 50% (group 2), a difference in response
to propafenone was observed. Thirteen patients constituting
group 2 had a baseline ejection fraction of 32%, which was
reduced during propafenone therapy to 24% (p < 0.05).
Average propafenone blood level in patients in group 2 was
730 ng/ml, The 11 patients in group 1 with a normal baseline
PROPAFENONE 900mg/day
Figure 4. Tracings from a responderto propafenone dur-
ing noninvasive and invasive phase 2 studies. A, In the
control study, frequent ventricularprematurebeats (grade
2), couplets (grade 4A) and salvos of ventricular tachy-
cardia are provoked by exercise. During an electrophys-
iologic test (bottom), two extrastimuli (S" S2) during
ventricular pacing (p) provoke ventricular fibrillation (YF).
B, After4 daysof propafenone therapy,ventricularectopic
activity (YEA) is eliminated. Althoughexercise duration
is increased, peak heart rate (hr) is reduced. Duringrepeat
electrophysiologic study (bottom), two extrastimuli pro-
vokeonly a multiplerepetitiveventricularresponse(mrvr)
of two cycles. With three extrasimuli (S2, S2, S,), only a
single repetitive response (srvr) is elicited.
o
CONTROL grade
rest 2 4A .4B
·~nW~
I I ~ ~
~'r""1'V'I'~~~~ 8
the acute drug test had ventricular arrhythmias abolished
during phase 2. The concordance rate between the two study
phases was therefore 91% (p < 0.01).
Electrophysiologic testing. Multiple repetitive re-
sponses were provoked in all nine patients who were sub-
jected to control electrophysiologic testing. In four patients,
nonsustained ventricular tachycardia was the end point. The
average number of cycles was 8 (range 6 to 10) with a cycle
length of 365 ms. In four patients, sustained ventricular
tachycardia was provoked and another patient had ventric-
ular fibrillation. The average rate of the ventricular tachy-
cardia was 192 beats/min (range 160 to 220). Seven patients
responded to the drug with both electrophysiologic and non-
invasive studies (Fig. 4). Two patients did not respond with
either approach for evaluating drug efficacy; thus, there was
100% concordance between invasive and noninvasive
methods.
Echocardiographic evaluation of left ventricular func-
tion (Table 4). Echocardiograms were obtained in 24 pa-
tients. In the group as a whole, propafenone did not alter
the ejection fraction (46 versus 43%, p = NS). However,
when patients were stratified into those with a normal ejec-
tion fraction of greater than 50% (group I) or an abnormal
JACC Vo. 4. No.1
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Control Drug
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End-systolic diameter (em)
End-systolic volume (rnl/nr')
End-diastolic diameter (em)
End-diastolic volume (ml/rrr')
Stroke volume index (ml/m 2)
Ejection fraction (%)
Baseline <50% (n = 13)
Baseline >50% (n = II)
4.5 ± 1.3
60 ± 33
6.3 ± 1.2
113 ± 43
52.2 ± 21
46
32
61
4.9 ± 1.3
67 ± 39
6.3 ± 1.2
113 ± 43
48.5 ± 15
43
24
60
NS
NS
NS
NS
NS
NS
<0.05
NS
Table 5. Side Effects in 30 Patients
in the accessory pathway of patients with the. Wolff-Par-
kinson-White syndrome (2,15).
Pharmacology of propafenone. Propafenone exhibits
mild beta-receptor blocking activity and inhibits the positive
inotropic and chronotropic effects of isoprenaline (17). Pro-
pafenone may also have calcium channel blocking activity
in view of the findings by Zeiler et al. (14) that the drug
decreases the amplitude of delayed afterpotentials and de-
pressed triggered automaticity. However, Ledda et al. (17)
found propafenone to be only 0.01 as potent as verapamil
in its calcium blocking properties. There are no studies in
human subjects demonstrating either beta-receptor or cal-
cium channel blocking activity. Our observations that pro-
pafenone significantly reduced the peak heart rate achieved
during exercise suggests that either beta-receptor blocking
or calcium channel blocking activity may indeed occur
clinically.
The half-life of propafenone is 3.6 hours after a single
dose (18), but is prolonged to 6.1 hours after multiple doses
(19). The drug is cleared from blood rapidly by the liver.
It has been reported (1,3,19) that there is a direct correlation
between the drug level and prolongation of PR interval and
QRS duration, but this was not observed in our study.
Clinical studies with propafenone. Only a few clinical
studies of propafenone therapy for arrhythmia have been
reported and most of these have involved supraventricular
disorders (1,20,21). The drug has been shown to be effective
in preventing supraventricular tachycardia, including those
associated with the Wo1ff-Parkinson-White syndrome (2).
It is of limited use for converting or preventing atrial fi-
brillation or flutter (1). Studies with propafenone in ven-
n = number of patients; NS = not significant.
ejection fraction (mean 61%) exhibited no reduction with
propafenone with the exception of 1 patient who had a
decrease from 56 to 31%. Average propafenone blood level
in the patients in group I was 758 ng/ml, which was not
different from the value in group 2.
Side effects (Table 5). Side effects were encountered in
9 of the 30 patients. Heart failure was exacerbated in two
patients, and in one patient propafenone had to be discon-
tinued before cardiac compensation could be restored. In
the other patient, a reduction in dose from 900 to 450 mg/day
sufficed. Two patients developed conduction abnormalities
consisting of bundle branch block in one patient and episodic
sinus arrest in the other. Two patients had aggravation of
arrhythmia (Fig. 5). Both developed sustained ventricular
tachycardia with syncope during phase 2 testing, although
in the control period they manifested only short salvos. The
average serum drug level in those with side effects was 855
ng/ml (range 234 to 1,478) (Table 2). This average level
was higher than in those without side efects, but the dif-
ference was not significant.
Chronic therapy. Ten patients were discharged on pro-
pafenone therapy. The average follow-up period has been
only 10 months (range 3 to 13). Thus far, none have had
recurrence of arrhythmia.
Discussion
Electrophysiologic properties. Propafenone is an an-
tiarrhythmic agent with membrane-stabilizing or local an-
esthetic activity (12). It interferes with sodium conductance,
thereby prolonging the upstroke velocity of the action po-
tential. In animals, it slows conduction and prolongs the
refractory period of normal atrial, atrioventricular and ven-
tricular tissue (13). These changes are more marked in the
ischemic myocardium (14). Findings in human studies par-
allel those observed in animal experiments. Neuss and
Schlepper (15) observed that propafenone prolonged con-
duction time in the atrium, atrioventricular node, His-Pur-
kinje system and ventricular tissue, with concomitant
lengtheningofPR intervaland QRS complex duration (15,16).
The drug also slows anterograde and retrograde conduction
Gastrointestinal
Dizziness
Congestive heart failure
Conduction disturbances
Aggravation of arrhythmia
Total
No. of
Patients
3
I
2
2
2
9(30%)
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Figure 5. Exampleof aggravation of arrhythymia. Duringcontrol
studies (left), there were frequent ventricularpremature beats and
occasional salvos of ventricular tachycardia. After 4 days of pro-
pafenonetherapy (right), exercise testing provokes sustainedven-
tricular tachycardia with syncope, which required three defibril-
lation attempts ($) before sinus rhythm was restored.
tricular arrhythmia have primarily involved its effect on the
ventricular premature beat frequency; it abolishes about 80%
of ectopic beats, with drug efficacy directly related to the
daily dose administered (3,21-23). The use ofpropafenone
for sustained ventricular arrhythmias has been, so far, in-
adequately examined (1,24).
Our studies adhered to a specific protocol (6,9,25). Sus-
tained ventricular tachycardia with hemodynamic instability
or ventricular fibrillation had occurred in each patient. Ther-
apy with conventional antiarrhythmic drugs was either in-
effective or caused side effects. Evaluation of the drug effect
included both ambulatory monitoring and exercise testing.
Propafenone was judged effective in 53% of patients. This
was based on a 99% decrease in couplets, the complete
abolition of paroxysms of ventricular tachycardia and a 93%
reduction in the frequency of ventricular premature beats.
Of interest is that acute drug testing with a single large dose
of propafenone predicted the response during phase 2 main-
tenance therapy in 91% of patients, a result similar to earlier
experience with quinidine (26), mexiletine (27) and pindolol
(28).
Hemodynamic effects. An important concern is the ef-
fect of antiarrhythmic drugs on left ventricular function and
their safety in patients with congestive heart failure. Sig-
nificant negative inotropic activity has been observed with
propafenone (13,29). When administered intravenously, blood
pressure and left ventricular contractile force are reduced
(13). Utilizing two-dimensional echocardiography, Salerno
et al. (24) reported that propafenone lowered ejection frac-
tion from 34 to 30%. Baker et al. (29), utilizing radionuclide
scanning, reported a 20% reduction in ejection fraction when
left ventricular dysfunction was present, while no such effect
was noted in those with a normal heart. In our study, em-
ploying M-mode echocardiography in patients with abnor-
mal left ventricular function, propafenone increased end-
systolic volume and decreased the ejection fraction. Only
one patient with an ejection fraction of greater than 50%
had a reduction in this value. Two patients (14%) developed
overt congestive heart failure while receiving propafenone.
Both had a history of congestive heart failure.
Side effects. Mild side effects have been observed in 5
to 30% of patients and consist primarily of dizziness and
gastrointestinal symptoms (22,30). However, potentially se-
rious conduction abnormalities including sinus arrest and
atrioventricular block have been reported (30). Similar to
our experience with other drugs (31), propafenone can cause
aggravation of arrhythmia. The two patients who had an
increase in arrhythmia did not have any associated QT pro-
longations or QRS complex widening.
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Propafenone proved an effective antiarrhythmic agent in
about naif our patients with life-threatening ventricular ar-
rhythmias. It exerts a negative inotropic effect and, like
other antiarrhythmics agents, may aggravate an arrhythmia.
The drug may depress conduction and should be used cau-
tiously in patients with conduction system disease.
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